2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Agios Pharma (AGIO)

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

What makes Intellia Therapeutics (NTLA) an interesting investment?

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...
Healio

FDA declines to approve relacorilant for hypertension linked to hypercortisolism

The FDA has issued a complete response letter for an oral selective glucocorticoid receptor antagonist under investigation ...
Investing.com UK

U.S. December unemployment rate estimated at 4.6% by Chicago Fed

The Chicago Federal Reserve estimated on Tuesday that the U.S. unemployment rate remained at 4.6% in December, unchanged from November’s official rate. The Nove ...
Seeking Alpha

TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and ...

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...